BioNTech SE (ETR:22UA)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.63B +3.2% |
| Revenue (ttm) | 2.65B -7.9% |
| Net Income | -1.69B |
| EPS | -6.80 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,845 |
| Open | 86.15 |
| Previous Close | 86.90 |
| Day's Range | 85.55 - 86.90 |
| 52-Week Range | 68.30 - 105.70 |
| Beta | 1.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli... [Read more]
Financial Performance
In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.
Financial StatementsNews
BioNTech to shutter sites in Germany, Singapore as no buyers emerge
German COVID‑19 vaccine maker BioNTech said on Monday it would close sites in Germany and Singapore because it failed to find buyers after pivoting away from pandemic-era manufacturing.
BioNTech says lung cancer drug candidate prolonged lives in trial
BioNTech said on Monday that a late-stage trial showed its drug candidate gotistobart led to a clinically meaningful overall survival benefit in a certain form of lung cancer compared with stan...
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-p...
BioNTech to terminate mid-stage trial of mRNA cancer vaccine
BioNTech SE said on Friday it has decided to terminate the mid-stage trial of its experimental mRNA-based cancer vaccine for patients with a type of colorectal cancer, sending the German firm's U.S...
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved t...
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
MAINZ, Germany, August 20, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its diversified development program in lung cancer treatment at the IASLC ...
BioNTech SE Earnings Call Transcript: Q2 2026
Q2 2026 saw revenues decline year-over-year due to lower COVID-19 vaccine demand and absence of one-time revenue, while oncology pipeline advanced with multiple pivotal trials and robust clinical data. Revised 2026 guidance reflects weaker vaccine demand, but strong cash reserves and disciplined capital allocation support continued investment in late-stage assets.
BioNTech SE Earnings release: Q2 2026
BioNTech SE released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
BioNTech SE Slides: Q2 2026
BioNTech SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
German vaccine maker BioNTech lowered its full year sales outlook range on Tuesday due to softer-than-expected COVID-19 vaccine demand and the timing of milestone-related revenues.
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer , taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal cli...
BioNTech says Sobi's Oelkers will replace Sahin as CEO
German biotech firm BioNTech said on Monday that Sobi's CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Manageme...
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authori...
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Ad...
BioNTech held buyer talks over four German sites set to close, Handelsblatt reports
BioNTech has held confidential talks with potential buyers about the German sites that the COVID‑19 vaccine maker plans to close, which has now grown to four locations, the Handelsblatt newspaper r...
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel tol...
Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1...
This Biotech's Cancer Portfolio Could End Its Rough Patch
The drugmaker is looking to its oncology pipeline to drive its next leg of growth.
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam...
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was ...
BioNTech SE Transcript: AGM 2026
The AGM highlighted strong financials, strategic focus on oncology, and major leadership transitions. All management proposals, including board expansion and capital measures, were approved by large majorities. Manufacturing consolidation and a $1B share buyback were key initiatives.
BioNTech Announces New ADS Repurchase Program
MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under whi...